| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 03/10/2011 | US20110059106 Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
| 03/10/2011 | US20110059103 Future cardiac event biomarkers |
| 03/10/2011 | US20110059085 Staphylococcus aureus-specific antibody preparations |
| 03/10/2011 | US20110059084 Agent for treating disease |
| 03/10/2011 | US20110059082 Agent for treating disease |
| 03/10/2011 | US20110059078 Anti-ifnar1 antibodies with reduced fc ligand affinity |
| 03/10/2011 | US20110059075 Aglycosylated immunoglobulin mutants |
| 03/10/2011 | US20110059073 Method for treating infectious disease using monoclonal antibodies |
| 03/10/2011 | US20110059072 Method for treating cancer using monoclonal antibodies |
| 03/10/2011 | US20110059068 Polypeptides involved in immune response |
| 03/10/2011 | US20110059067 Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
| 03/10/2011 | US20110059064 Vm23 and Vm24, two scorpion peptides that block human T-lymphocyte potassium channels (sub-type Kv1.3) w/High Selectivity and Decrease the in vivo DTH-responses in Rats |
| 03/10/2011 | US20110059056 Method for the Generation of Genetically Modified Vertebrate Precursor Lymphocytes and Use Thereof for the Production of Heterologous Binding Proteins |
| 03/10/2011 | US20110059041 Vaccine for treatment and prevention of herpes simplex virus infection |
| 03/10/2011 | US20110059021 Process for preparing variant of erysipelothrix rhusiopathiae surface protective antigen in e. coli |
| 03/10/2011 | US20110059015 Vaccine |
| 03/10/2011 | US20110059012 Identification of cd8+ t cells that are cd161hi and/or il18r (alpha) hi and have rapid drug efflux capacity |
| 03/10/2011 | CA2846746A1 Pcsk9 vaccine |
| 03/10/2011 | CA2773176A1 Treatment of diseases caused by bacterial exotoxins |
| 03/10/2011 | CA2773083A1 Immunity-inducing agent |
| 03/10/2011 | CA2772975A1 Novel multifunctional peptidase inhibitors, especially for medical use |
| 03/10/2011 | CA2772916A1 Immunogenic compositions including tlr activity modulators |
| 03/10/2011 | CA2772871A1 Pharmaceutical formulations for indibulin |
| 03/10/2011 | CA2772613A1 Anti-gitr antibodies |
| 03/10/2011 | CA2772567A1 Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof |
| 03/10/2011 | CA2772198A1 Picrorhiza kurroa extract for prevention, elimination and treatment of rna viruses and infection or diseases caused by the same in humans, animals and in biotech industry |
| 03/10/2011 | CA2772076A1 Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| 03/10/2011 | CA2771822A1 Bruton's tyrosine kinase inhibitors |
| 03/09/2011 | EP2292772A1 HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide |
| 03/09/2011 | EP2292770A2 Methods and means for producing proteins with predetermined post-translational modifications |
| 03/09/2011 | EP2292758A2 Uses of mammalian cytokine; related reagents |
| 03/09/2011 | EP2292734A1 Hematopoietic cells from human embryonic stem cells |
| 03/09/2011 | EP2292663A2 Antagonistic human light-specific human monoclonal antibodies |
| 03/09/2011 | EP2292660A2 Human antibody molecules for IL-13 |
| 03/09/2011 | EP2292655A1 Peptides and related molecules that bind to tall-1 |
| 03/09/2011 | EP2292652A2 Interferons uses and compositions related thereto |
| 03/09/2011 | EP2292642A1 Immunomodulating compositions, uses therefor and processes for their production |
| 03/09/2011 | EP2292634A2 Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
| 03/09/2011 | EP2292632A2 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 03/09/2011 | EP2292614A1 Substituted pyrimidines as aurora kinase inhibitors |
| 03/09/2011 | EP2292613A1 Dihydroindolinone derivatives |
| 03/09/2011 | EP2292595A1 Potassium channel modulators |
| 03/09/2011 | EP2292589A1 Novel multifunctional peptidase inhibitors, especially for medical use |
| 03/09/2011 | EP2292301A2 Anti-interferon-alpha antibodies |
| 03/09/2011 | EP2292273A2 Remodeling and glycoconjugation of peptides |
| 03/09/2011 | EP2292271A2 Remodelling and glycoconjugation of an antibody |
| 03/09/2011 | EP2292262A2 Use of modified novirhabdoviruses to obtain vaccines |
| 03/09/2011 | EP2292247A2 Immunizing composition and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein |
| 03/09/2011 | EP2292239A2 Remedies for diseases to be applied to eye |
| 03/09/2011 | EP2292235A2 Methotrexate solutions |
| 03/09/2011 | EP2292233A2 Pharmaceutical uses of N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine |
| 03/09/2011 | EP2292232A1 Beta-amino tetrahydroimidazo(1,2-A)pyrazines and tetrahydrotriazolo(4,3-A)pyrazines for use in the treatment of diabetes type II |
| 03/09/2011 | EP2292223A1 Polyunsaturated fatty acid supplements |
| 03/09/2011 | EP2292097A2 Recombinant parainfluenza virus expression systems and vaccines |
| 03/09/2011 | EP2292091A1 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
| 03/09/2011 | EP2291406A1 An anti-cancer cytotoxic monoclonal antibody |
| 03/09/2011 | EP2291401A2 Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
| 03/09/2011 | EP2291196A2 Staphylococcus aureus-specific antibody preparations |
| 03/09/2011 | EP2291190A2 Vaccine composition containing synthetic adjuvant |
| 03/09/2011 | EP2201006B1 (r)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them |
| 03/09/2011 | EP1888122B1 A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of tnf alpha and a carrier protein |
| 03/09/2011 | EP1842857B1 Mutant interferon proteins and use thereof |
| 03/09/2011 | EP1796713B1 Use of gilz proteinto modulate an antigen-specific immune response |
| 03/09/2011 | EP1753765B1 Immuno inhibitory heterocyclic compounds |
| 03/09/2011 | EP1748069B1 Follistatin mutant polypeptide |
| 03/09/2011 | EP1709080B1 ANTIBODIES TO MAdCAM |
| 03/09/2011 | EP1355910B1 Formulation of boronic acid compounds |
| 03/09/2011 | EP1315513B1 "pseudo"-native chemical ligation |
| 03/09/2011 | EP1181320B1 Somatic transgene immunization and related methods |
| 03/09/2011 | EP1088098B1 Medicament for treating hiv-infected mammals |
| 03/09/2011 | CN101984036A Health vinegar and preparation method thereof |
| 03/09/2011 | CN101984034A Health-care wine |
| 03/09/2011 | CN101983969A Method of preparing ginkgo protein superfine powders |
| 03/09/2011 | CN101983703A Traditional Chinese medicine composition and traditional Chinese medicine preparation |
| 03/08/2011 | US7902360 e.g. 3-[2-(4-aminophenyl)ethyl]-8-benzyl-7-(2-ethylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility |
| 03/08/2011 | US7902208 Treating allergic and inflammatory conditions |
| 03/08/2011 | US7902187 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| 03/08/2011 | US7902179 Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease |
| 03/08/2011 | US7902175 Aminopropanol derivatives |
| 03/08/2011 | US7902162 Medicament and method for treating recurrent spontaneous abortion |
| 03/08/2011 | US7902151 Methods and compositions for modulating immunity |
| 03/08/2011 | US7902144 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 03/08/2011 | US7901894 Kinase inhibitors |
| 03/08/2011 | US7901879 Also stimulating interleukin-18 or GM-CSF by administering lactoferrin |
| 03/08/2011 | US7901716 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 03/08/2011 | US7901709 Active agent, a gel-phase lipid bilayer membrane of a phospholipid and a surface active agent contained in the bilayer membrane; increasing the percentage of active agent released at the phase transition temperature of the lipid bilayer |
| 03/08/2011 | US7901676 Therapeutic composition for the treatment of rheumatoid arthritis |
| 03/08/2011 | US7901672 Methods of making enhanced, autologous fat grafts |
| 03/08/2011 | CA2488202C 1-aryl-4-substituted piperazine derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders |
| 03/08/2011 | CA2486915C Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 03/08/2011 | CA2483764C Arsenic therapy for apls-type autoimmune lymphoproliferative syndrome in mice and humans |
| 03/08/2011 | CA2468415C Non-human animal model of systemic lupus erythematosus |
| 03/08/2011 | CA2464721C Nitrogenous (tetrahydropyridyl) (alkyl) heterocycles with tnf activity |
| 03/08/2011 | CA2460313C Bisphenylsulfanyl and sulphonate compounds and use thereof for elevating hdl cholesterol levels |
| 03/08/2011 | CA2338504C Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| 03/08/2011 | CA2137377C Retinal pigmented epithelium derived neurotrophic factor |
| 03/03/2011 | WO2011024987A1 Aromatic fused heterocyclic derivative and pharmaceutical composition containing same |
| 03/03/2011 | WO2011024973A1 Therapeutic agent for rhinitis |
| 03/03/2011 | WO2011024918A1 Antiangiogenic agent and method for inhibition of angiogenesis |
| 03/03/2011 | WO2011024874A1 Base addition salts |